Diabetes in pregnancy

advertisement

Diabetes in pregnancy- an update

Seema Chakravarti

MRCOG, MRCPI

Consultant Obstetrician BHR

Trust

CEMACH DIABETES REPORT

 Perinatal mortality 5 fold increased

 3 fold increase in neonatal deaths in first month of life

 2 fold increase in cong abnormalities

(NTD/Cardiac)

 Adverse outcomes same for type 1 and 2 DM

 Prem delivery 5 fold, macrosomia

 High csection rate 70%

 Severe PET

Subtypes

 Type 1

 Type 2

 Gestational Diabetics

 SOME WOMEN WITH

GDM WILL HAVE PRE

EXISTING DIABETES!!

Factors associated with poor pregnancy outcome

 Maternal social deprivation

 Lack of contraceptive use in 12 months preceding pregnancy

 No folic acid intake pre pregnancy 5mg

 Suboptimal diabetes management

 Suboptimal preconception care

 Suboptimal glycemic control before and during pregnancy

Key recommendations for specialist preconception services

 Multidisciplinary- diabetic physician/obstetrician/midwife/diabetic nurse

 Appropriate contraception

 High dose folic acid supplementation

 Assess and manage diabetic complications

 Optimise glycemic control HbA1c <7

 Counsel regarding risks and management strategies

Booking HbA1c and pregnancy outcome

Pregnancy putcome by booking

HbA1c

100%

80%

60%

40%

20%

0%

<7.8 >7.8>14

14

Hb A1c

SB

Cong abnormality

Normal

Solutions

 Pre- conception counselling- good diabetic control at conception and pregnancy reduce incidence of miscarriage, malformation, SB and NND

 Contraceptive advice, importance of avoiding unplanned preg should be an essential component of diabetic education for all diabetic women DOCUMENT

 Only 1/3 women currently get PPC, 40% pregnancies unplanned

Targets

 Pre conception Hb A1c <7.0% if safe

 Increase frequency of self monitoring

 Pre meal 5.5 mmol/l

 Post meal 7.7mmol/l

 Retinal screening treat pre pregnancy if proliferative retinopathy

 Assess nephropathy- PCR/renal biochem

 Review medication

Review medication

 Stop ACE inhibitors discuss pros and cons

 Beta blockers with caution as higher R/O

IUGR

 Methyl dopa, nifedepine,hydralazine

 Stop statins

 Metformin/glibenclamide can be used in pregnancy, early referral

Assess diabetes

 Retinopathy digital pictures and mydriasis

 If retinopathy need preconception advice and possible treatment

Percentage of women developing sight threatening DR in pregnancy

30

20

10

0

60

50

40

No retinopathy

Minimal retinopathy

Mod to severe retinopathy

Nephropathy

1.

2.

3.

Warn risk of PET/IUGR/SB

Refer for hospital PPC if creatinine more than 120micromole/litre and 24 hr urine protein >2gm

Consider asprin/clexane especially if proteinuria as increased thromboembolic risk

General advice

 Diet and lifestyle

 Optimise weight( BMI>35 independent risk factor for maternal mortality and morbidity)

 Adequate contraception

 Folic Acid 5mg until 12 weeks gestation.

Diabetes UK and CEMACH guidance on pre preg care Leaflet

Other changes

 Can continue/start metformin/glibenclamide in pregnancy

HAPO Trial- safe, no increased risk of malformations, better control in Type 2

Dimples hypos with tighter control

Watch for lactic acidosis – euglycemic acidosis

Breast feeding

 Metformin safe NICE

 Thank you

Download